Arrowhead pays $215M PRV for Redemplo; Twist targets $300M offering; Mironid raises $46M; and more.
August 5, 2026 10:28 AM EDT
Arrowhead buys PRV for $215M; Twist hopes to raise $300M in public offering
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
Verastem eyes accelerated approval for KRAS G12D drug in 3 cancers; ADC Therapeutics cuts 17% of staff in restructuring.
Apogee details its $10.9B AbbVie buyout, the UK launches a drug-pricing pilot, and Brii shares Phase 2b HBV vaccine data.
Cartesian’s $150M financing; Editas Medicine’s money moves
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for…
Angitia halts a Phase 3 disc-disease trial, Abivax prices an upsized $800M offering, and AlzeCure lands a $2.2B NeuroRestore deal…
